Metabolic syndrome – which the American Heart Association estimates affects approximately 1/3 of adults in the U.S. – is a constellation of conditions that manifests as diseases such as obesity, type 2 diabetes, high blood pressure, elevated lipid levels and fatty liver. Addressing the complex nature of these fundamental metabolic conditions requires a multi-faceted approach to drug development. NGM’s high-throughput in vivo screening capabilities enable us to evaluate potential therapeutics in relevant disease models and to study pharmacological effects on the complex multi-organ processes that regulate systemic metabolism.
NGM’s ability to elucidate key biological mechanisms and determine protein structure-pharmacological function relationships led to the discovery of multiple first-in-class drug candidates. NGM believes the initial candidates in our portfolio reflect a deep understanding of the biology and diseases that we are addressing and have the potential to be transformative therapeutics for a large and growing population of patients with these conditions.